Comparative Pharmacology
Head-to-head clinical analysis: AMILORIDE HYDROCHLORIDE versus CAROSPIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMILORIDE HYDROCHLORIDE versus CAROSPIR.
AMILORIDE HYDROCHLORIDE vs CAROSPIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amiloride hydrochloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct of the nephron, inhibiting sodium reabsorption and reducing potassium and hydrogen ion secretion.
Aldosterone antagonist; competitively inhibits aldosterone binding to mineralocorticoid receptors in renal distal tubules, increasing sodium and water excretion while retaining potassium. Also has weak antagonistic activity at androgen receptors.
5-10 mg orally once daily; maximum 20 mg/day.
Spironolactone 25-100 mg orally once daily. Initial: 25 mg once daily; titrate at 4-week intervals based on response and potassium levels. Maximum: 100 mg/day.
None Documented
None Documented
Terminal elimination half-life is 6-9 hours; prolonged to 20-24 hours in renal impairment
Spironolactone has a short half-life of 1.3-2.0 hours, but its active metabolite canrenone has a prolonged half-life of 13-24 hours (mean 18 hours), leading to a sustained pharmacodynamic effect requiring 2-3 days to reach steady state.
Renal, approximately 50% unchanged; minor biliary/fecal elimination (<10%)
Approximately 50-60% of the dose is excreted in urine as active metabolites (primarily canrenone) and unchanged drug, with about 10-20% as unchanged spironolactone. Fecal excretion accounts for 20-30%, mainly as metabolites.
Category C
Category C
Potassium-Sparing Diuretic
Potassium-Sparing Diuretic